Advanced Search Results

Title
---
Authors and Affiliations
andrea fava

1
2
3
…
5
Next Page »

Search Again »

Abstract Number: 2679 • ACR Convergence 2024
Predictors of Fracture in SLE: A Longitudinal Cohort Study
Kristen Chao¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Fractures are one of the most common damage items in the SLICC/ACR Damage Index. Although commonly attributed to corticosteroid use, the complexity of ways…
Abstract Number: 0607 • ACR Convergence 2024
Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Andrea Fava¹, Michelle Petri², David Jayne³, Patrick G Gavin⁴, Eszter Csomor⁵, Philip Z Brohawn⁴, Daniel Muthas⁶, Adam Platt⁵, Catharina Lindholm⁷ and Nicola Ferrari⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of Cambridge, Cambridge, United Kingdom, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
Abstract Number: 0811 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Longitudinal Serum Samples to Predict Treatment Response in Lupus Nephritis
Benjamin Jones¹, Rufei Lu², Andrea Fava³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steven Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Judith James¹³ and Joel Guthridge¹³, ¹Oklahoma State University, Oklahoma City, OK, ²University of California San Francisco, San Bruno, CA, ³Johns Hopkins University, Baltimore, MD, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Lupus nephritis (LN) can lead to severe morbidity and early mortality in SLE patients. While therapeutic options for LN have improved, they are not…
Abstract Number: 0905 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes
Rufei Lu¹, Andrea Fava², Benjamin Jones³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steve Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Richard Furie¹⁷, Judith James¹³ and Joel Guthridge¹³, ¹University of California San Francisco, San Bruno, CA, ²Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Oklahoma State University, Oklahoma City, OK, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷Northwell Health, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
Abstract Number: 1493 • ACR Convergence 2024
How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline
Jorge Guerra Sayre¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of SLE patients, contributing significant morbidity and mortality. Despite a generally accepted treatment goal of Complete Renal…
Abstract Number: 1642 • ACR Convergence 2024
A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Andrea Fava¹, Andrew Concoff², Tyler O'Malley³, Sepehr Taghavi⁴, Touba Warsi⁴, Sudha Kumar⁴, Christine Schleif⁴ and Michelle Petri⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Vista, CA, ⁴Exagen, Carlsbad, CA, ⁵Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Achieving an NIH Activity Index of < 2 upon treatment is associated with less LN flare and thus better long-term kidney survival. Here, we…
Abstract Number: 1686 • ACR Convergence 2024
Urine Proteomics in Class II Lupus Nephritis Reveals Immune Activation and Pro-Fibrotic Signatures
Jasmine Shwetar¹, Jill Buyon², Michelle Petri³, Kelly Ruggles⁴ and Andrea Fava⁵, ¹New York School of Medicine, Ann Arbor, MI, ²NYU Grossman School of Medicine, New York, NY, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU Grossman School of Medicine, Brooklyn, NY, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) is a pathologically diverse autoimmune disease that can lead to end-stage kidney disease and mortality. Although Class II LN is considered…
Abstract Number: 1798 • ACR Convergence 2024
CXCL6 Synthesized by Proximal Tubule Cells May Promote Fibrosis in Lupus Nephritis
Philip Carlucci¹, Nalani Sachan², Andrea Fava³, Brooke Cohen², Jasmine Shwetar⁴, Siddarth Gurajala⁵, Qian Xiao⁵, Joseph Mears⁶, Katie Preisinger², Devyn Zaminski⁷, Kristina Deonaraine⁸, Peter Izmirly⁹, Judith James¹⁰, Joel Guthridge¹⁰, Wade DeJager¹¹, David Wofsy¹², Cynthia Loomis², Gyles Ward², Ming Wu¹³, Chaim Putterman¹⁴, Deepak Rao¹⁵, Betty Diamond¹⁶, Derek Fine¹⁷, Jose Monroy-Trujillo¹⁷, H Michael Belmont⁷, William Apruzzese¹⁸, Anne Davidson¹⁹, Richard Furie²⁰, Paul Hoover²¹, Celine Berthier²², Maria Dall'Era²³, Diane Kamen²⁴, Kenneth Kalunian²⁵, Jennifer Anolik²⁶, Jennifer Barnas²⁷, Arnon Arazi²⁸, Soumya Raychaudhuri²⁹, Nir Hacohen³⁰, Robert Clancy³¹, Kelly Ruggles³², Michelle Petri³³ and Jill Buyon², and the Accelerating Medicines Partnership in RA/SLE, ¹New York University School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³Johns Hopkins University, Baltimore, MD, ⁴New York School of Medicine, Ann Arbor, MI, ⁵Harvard Medical School, Boston, MA, ⁶Michigan University, Ann Arbor, MI, ⁷NYU School of Medicine, New York, NY, ⁸Jacobs School of Medicine, University at Buffalo, Buffalo, NY, ⁹New York University Grossman School of Medicine, New York, NY, ¹⁰Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, ¹²University of California San Francisco, SF, CA, ¹³Northwell, New York, NY, ¹⁴Albert Einstein College of Medicine, Safed, Israel, ¹⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁶The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁷Johns Hopkins School of Medicine, Baltimore, MD, ¹⁸Brigham and Women's Hospital, Everett, MA, ¹⁹Feinstein Institutes for Medical Research, Manhasset, NY, ²⁰Northwell Health, Manhasset, NY, ²¹Brigham and Women's Hospital, SWAMPSCOTT, MA, ²²University of Michigan, Ann Arbor, MI, ²³UCSF, Corte Madera, CA, ²⁴Medical University of South Carolina, Charleston, SC, ²⁵University of California San Diego, La Jolla, CA, ²⁶University of Rochester Medical Center, Rochester, NY, ²⁷University of Rochester, Rochester, NY, ²⁸Feinstein Institutes for Medical Research, Melrose, MA, ²⁹Brigham and Women's Hospital, Boston, MA, ³⁰Broad Institute of MIT and Harvard, Boston, MA, ³¹Columbia University Medical Center, New York, NY, ³²NYU Grossman School of Medicine, Brooklyn, NY, ³³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Detection of urinary CXCL6, a member of the IL-8 chemokine family, has been linked to CKD and is a proposed marker of chronic damage…
Abstract Number: 1802 • ACR Convergence 2024
Heterogeneous Neutrophil Subsets Infiltrate Glomeruli of Lupus Nephritis Patients and Are Elevated in the Kidneys and Urine of Sunlight-induced Nephritis Flares
Noelle Kosarek¹, Joshua Skydel², Alecia Roy³, Fred Kolling¹, Lucas Salas¹, Christopher Burns⁴, Andrea Fava⁵ and Sladjana Skopelja-Gardner¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, ²Dartmouth Hitchcock Medical Center, Lebanon, ³Dartmouth College, Lebanon, NH, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁵Divison of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Up to ~60% of SLE patients in North America will develop kidney disease, lupus nephritis (LN), one of the main contributors to disease morbidity…
Abstract Number: 1811 • ACR Convergence 2024
The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach
Chen-Yu Lee¹, Matthew Caleb Marlin², Xiaoping Yang¹, Alessandra Ida Celia³, Vasileios Morkotinis⁴, Richard Furie⁵, Jill Buyon⁶, Chaim Putterman⁷, Jennifer Barnas⁸, Kenneth Kalunian⁹, Peter Izmirly¹⁰, Betty Diamond¹¹, Anne Davidson¹², Diane Kamen¹³, Jeff Hodgin¹⁴, the Accelerating Medicines Partnership RA/SLE¹⁵, Judith James², Michelle Petri¹⁶, Joel Guthridge², Avi Rosenberg¹ and Andrea Fava¹, ¹Johns Hopkins UNiversity, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Sapienza University of Rome, Rome, Italy, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Northwell Health, Manhasset, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Safed, Israel, ⁸University of Rochester, Rochester, NY, ⁹University of California San Diego, La Jolla, CA, ¹⁰New York University Grossman School of Medicine, New York, NY, ¹¹The Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Michigan, Michigan, ¹⁵multiple, multiple, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment response rates in lupus nephritis (LN) remain suboptimal, highlighting the need for a better understanding of LN pathogenesis to enhance treatment strategies. Single-cell…
Abstract Number: 2372 • ACR Convergence 2024
Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
Yoo Jin Kim¹, Jana Lovell¹, Alaa Diab¹, Laurence Magder², Daniel Goldman³, Michelle Petri³, Luigi Adamo¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Baltimore, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus (SLE). In the general population, pericarditis commonly recurs (~30%), likely due to immune-mediated…
Abstract Number: 2413 • ACR Convergence 2024
The Natural History of SLE Has Changed Since the 1970s
Adaobi Ugochukwu¹, Daniel Goldman², Andrea Fava³, Laurence Magder⁴ and Michelle Petri², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: We investigated the changes in the prevalence of specific SLE manifestations over the last 50 years. In addition, we looked for differences between African-Americans…
Abstract Number: 1695 • ACR Convergence 2023
Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis
Philip Carlucci¹, Jasmine Shwetar², Siddarth Gurajala³, Qian Xiao³, Joseph Mears⁴, Katie Preisinger¹, Devyn Zaminski⁵, Kristina Deonaraine¹, Peter Izmirly¹, Andrea Fava⁶, Judith James⁷, Joel Guthridge⁷, Brad Rovin⁸, Sethu Madhavan⁸, Wade DeJager⁷, David Wofsy⁹, Ming Wu², Chaim Putterman¹⁰, Deepak Rao¹¹, Betty Diamond¹², Derek Fine¹³, Jose Monroy-Trujillo¹³, Kristin Haag¹⁴, H Michael Belmont⁵, William Apruzzese¹¹, Anne Davidson¹², Fernanda Payan-Schober¹⁵, Richard Furie¹⁶, Paul Hoover¹¹, Celine Berthier¹⁷, Maria Dall'Era⁹, Kerry Cho¹⁸, Diane L. Kamen¹⁹, Kenneth Kalunian²⁰, Jennifer Anolik²¹, Arnon Arazi²², Soumya Raychaudhuri¹¹, Nir Hacohen²³, Michelle Petri²⁴, Robert Clancy²⁵, Kelly Ruggles², Jill Buyon²⁵ and The Accelerating Medicines Partnership in RA/SLE²⁶, ¹New York University School of Medicine, New York, NY, ²NYU Langone, New York, NY, ³Harvard Medical School, Boston, MA, ⁴Michigan University, Ann Arbor, MI, ⁵NYU School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Ohio State University, Columbus, OH, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Albert Einstein College of Medicine, Bronx, NY, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Johns Hopkins School of Medicine, Baltimore, MD, ¹⁴Thomas Jefferson University, Philadelphia, PA, ¹⁵Texas Tech University Health Sciences Center, El Paso, TX, ¹⁶Northwell Health, Manhasset, NY, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸UCSF Health, San Francisco, CA, ¹⁹Medical University of South Carolina, Charleston, SC, ²⁰University of California San Diego, La Jolla, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Broad Institute of MIT and Harvard, Melrose, MA, ²³Broad Institute of MIT and Harvard, Cambridge, MA, ²⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁵NYU Grossman School of Medicine, New York, NY, ²⁶Multiple, Bethesda, MD
Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…
Abstract Number: 2327 • ACR Convergence 2023
Hydroxychloroquine Improves Low Complement Levels
Michelle Petri¹, Rebecca Jacobson², Andrea Fava³ and Larry Magder⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: Low complement is associated with clinical disease activity and future organ damage in patients with systemic lupus erythematosus (SLE). Prior studies from Japan, although…
Abstract Number: 2427 • ACR Convergence 2023
Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis
Alessandra Ida Celia¹, Xiaoping Yang², Hana Minsky², Silvia Malvica², Michelle Petri³, the Accelerating Medicines Partnership in RA/SLE⁴, Avi Rosenberg⁵ and Andrea Fava², ¹John Hopkins University of Medicine, Rome, Italy, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴Multiple, Multiple, ⁵Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: As part of the Accelerating Medicines Partnership (AMP), we discovered that urinary PR3, a neutrophil degranulation product, is associated with histological activity, indicating the…

1
2
3
…
5
Next Page »

Search Again »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].